<p>Thrivent Financial for Lutherans 在最近向美国证券交易委员会（SEC）披露的信息中表示，在第四季度将其在 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的股份增加了 1,821.0%。该机构投资者在该生物技术公司购买了额外的 1,126,256 股后，持有 1,188,105 股 Exelixis 的股票。Thrivent Financial for Lutherans 在最近的报告期末持有 Exelixis 约 0.44% 的股份，价值 52,075,000 美元。</p>
<ul>
<li>Exelixis 报告稳健的收益——新的高点是否重回视野？</li>
</ul>
<p>其他机构投资者最近也增加或减少了在该公司的股份。Richardson Financial Services Inc. 在第三季度将其在 Exelixis 的持仓提高了 95.1%。Richardson Financial Services Inc. 目前持有 599 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度购买了额外的 292 股。Anchor Investment Management LLC 在第三季度将其在 Exelixis 的持仓提高了 500.0%。Anchor Investment Management LLC 目前持有 600 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度购买了额外的 500 股。Root Financial Partners LLC 在第三季度购买了 Exelixis 的新股份，价值约 28,000 美元。Activest Wealth Management 在第四季度获得了 Exelixis 的新股份，价值 32,000 美元。最后，Northwestern Mutual Wealth Management Co. 在第三季度将其在 Exelixis 的持仓增加了 1,380.4%。Northwestern Mutual Wealth Management Co. 目前持有 829 股该生物技术公司的股票，价值 34,000 美元，此前在上个季度获得了额外的 773 股。对冲基金和其他机构投资者持有该公司 85.27% 的股份。</p>
<h2>内部人士下注</h2>
<p>在相关消息中，董事 Maria C. Freire 于 5 月 7 日星期四出售了 20,634 股公司的股票。该股票以平均价格 46.00 美元出售，总交易额为 949,164.00 美元。交易完成后，该董事直接持有 100,819 股公司的股票，价值 4,637,674 美元。此次交易使其持仓减少了 16.99%。该交易在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，董事 George Poste 于 5 月 7 日星期四出售了 60,000 股公司的股票。该股票以平均价格 45.71 美元出售，总价值为 2,742,600.00 美元。交易完成后，该董事直接持有 118,832 股公司的股票，价值 5,431,810.72 美元。此次交易使其持仓减少了 33.55%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了价值 17,014,813 美元的 382,811 股公司股票。内部人士持有公司 2.60% 的股份。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>3 只股票值得购买，以应对软着陆，如果真的有的话</li>
</ul>
<p>EXEL 最近成为几份分析师报告的主题。加拿大皇家银行在 3 月 2 日的研究报告中将 Exelixis 的目标价从 46.00 美元下调至 43.00 美元，并对该公司设定了 “行业表现” 评级。Truist Financial 在 4 月 27 日的研究报告中将 Exelixis 的评级提升至 “强力买入”。富国银行在 5 月 6 日的研究报告中将 Exelixis 的目标价从 35.00 美元上调至 40.00 美元，并给予该股票 “等权重” 评级。Stifel Nicolaus 在 5 月 6 日的研究报告中将 Exelixis 的目标价从 44.00 美元上调至 47.00 美元，并给予该股票 “持有” 评级。最后，TD Cowen 在 5 月 6 日的研究报告中将 Exelixis 的目标价从 51.00 美元上调至 55.00 美元，并给予该股票 “买入” 评级。一位研究分析师对该股票给予了 “强力买入” 评级，九位给予了 “买入” 评级，十一位给予了 “持有” 评级，二位对该公司的股票给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价为 47.35 美元。</p>
<p><strong>查看我们最新的 EXEL 股票报告</strong></p>
<h2>Exelixis 股价下跌 1.9%</h2>
<ul>
<li>3 只强劲的生物技术表现者，值得关注，因为该行业接近突破</li>
</ul>
<p>NASDAQ EXEL 的股票在周五开盘时为 50.13 美元。Exelixis, Inc. 的 12 个月低点为 33.76 美元，12 个月高点为 51.63 美元。该股票的 50 日简单移动平均为 44.30 美元，200 日简单移动平均为 43.48 美元。该股票的市值为 126 亿美元，市盈率为 16.65，市盈增长比率为 1.06，贝塔值为 0.38。</p>
<p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近于 5 月 5 日星期二发布了季度收益数据。该生物技术公司报告该季度每股收益为 0.87 美元，超出分析师的共识预期 0.75 美元，超出 0.12 美元。Exelixis 的股本回报率为 39.89%，净利润率为 35.08%。该公司在该季度的收入为 6.1081 亿美元，而分析师的预期为 6.0751 亿美元。在去年同期，该公司每股收益为 0.55 美元。该公司的收入同比增长 10.0%。平均而言，股票分析师预测 Exelixis, Inc. 在当前年度将发布每股收益 3.15 美元。</p>
<h2>关于 Exelixis</h2>
<p>（免费报告）</p>
<p>Exelixis, Inc. 是一家生物技术公司，专注于小分子疗法的发现、开发和商业化，主要用于癌症治疗。该公司基于利用模式生物遗传学和高通量筛选的平台，专注于调节肿瘤生长和转移相关的关键信号通路的激酶抑制剂的研究。Exelixis 的转化研究方法旨在将新化合物从早期发现推进到临床开发和监管批准。</p>
<p>该公司的最知名产品包括 CABOMETYX®（cabozantinib），已获批准用于治疗晚期肾细胞癌和肝细胞癌，以及用于转移性髓样甲状腺癌的 COMETRIQ®（cabozantinib）。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票超过 Exelixis</li>
<li>如果油价持续上涨，值得拥有的三只股票</li>
<li>分析师喜爱的三家关键航空航天组件制造商</li>
<li>Alphabet 的 Googlebook 将 Gemini AI 引入 PC 硬件</li>
<li>Peloton 股票在乐观的财报发布后回吐涨幅</li>
</ul>
<p><strong>想看看其他对 EXEL 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
<p>在考虑 Exelixis 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Exelixis 并不在名单上。</p>
<p>虽然 Exelixis 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

伊克力西斯

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

<p>Thrivent Financial for Lutherans 在第四季度显著增加了对 Exelixis, Inc. 的持股，增幅达到 1,821.0%，目前持有 1,188,105 股，价值 5200 万美元。其他机构投资者也提高了他们的持仓。内部人士最近出售了总计超过 1700 万美元的股票。分析师对 Exelixis 的评级褒贬不一，目标价格范围在 40 美元到 55 美元之间。该股票开盘价为 50.13 美元，市值为 126 亿美元</p>

<p>Thrivent Financial for Lutherans increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1,821.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,188,105 shares of the biotechnology company's stock after buying an additional 1,126,256 shares during the quarter. Thrivent Financial for Lutherans owned about 0.44% of Exelixis worth $52,075,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Thrivent Financial for Lutherans 在最近向美国证券交易委员会（SEC）披露的信息中表示，在第四季度将其在 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的股份增加了 1,821.0%。该机构投资者在该生物技术公司购买了额外的 1,126,256 股后，持有 1,188,105 股 Exelixis 的股票。Thrivent Financial for Lutherans 在最近的报告期末持有 Exelixis 约 0.44% 的股份，价值 52,075,000 美元。</p>
</div><ul>
<li>Exelixis Reports Solid Earnings—Are New Highs Back on the Table?</li>
</ul>
<div class="lb-trans"><ul>
<li>Exelixis 报告稳健的收益——新的高点是否重回视野？</li>
</ul>
</div><p>Other institutional investors have also recently added to or reduced their stakes in the company. Richardson Financial Services Inc. lifted its position in Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company's stock worth $25,000 after buying an additional 292 shares in the last quarter. Anchor Investment Management LLC lifted its position in Exelixis by 500.0% during the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company's stock worth $25,000 after buying an additional 500 shares in the last quarter. Root Financial Partners LLC purchased a new position in Exelixis during the third quarter worth approximately $28,000. Activest Wealth Management acquired a new stake in Exelixis during the fourth quarter worth $32,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Exelixis by 1,380.4% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 773 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也增加或减少了在该公司的股份。Richardson Financial Services Inc. 在第三季度将其在 Exelixis 的持仓提高了 95.1%。Richardson Financial Services Inc. 目前持有 599 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度购买了额外的 292 股。Anchor Investment Management LLC 在第三季度将其在 Exelixis 的持仓提高了 500.0%。Anchor Investment Management LLC 目前持有 600 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度购买了额外的 500 股。Root Financial Partners LLC 在第三季度购买了 Exelixis 的新股份，价值约 28,000 美元。Activest Wealth Management 在第四季度获得了 Exelixis 的新股份，价值 32,000 美元。最后，Northwestern Mutual Wealth Management Co. 在第三季度将其在 Exelixis 的持仓增加了 1,380.4%。Northwestern Mutual Wealth Management Co. 目前持有 829 股该生物技术公司的股票，价值 34,000 美元，此前在上个季度获得了额外的 773 股。对冲基金和其他机构投资者持有该公司 85.27% 的股份。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, Director Maria C. Freire sold 20,634 shares of the business's stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $46.00, for a total transaction of $949,164.00. Following the completion of the transaction, the director directly owned 100,819 shares of the company's stock, valued at $4,637,674. The trade was a 16.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director George Poste sold 60,000 shares of the business's stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $45.71, for a total value of $2,742,600.00. Following the transaction, the director directly owned 118,832 shares of the company's stock, valued at $5,431,810.72. The trade was a 33.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 382,811 shares of company stock valued at $17,014,813. Insiders own 2.60% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Maria C. Freire 于 5 月 7 日星期四出售了 20,634 股公司的股票。该股票以平均价格 46.00 美元出售，总交易额为 949,164.00 美元。交易完成后，该董事直接持有 100,819 股公司的股票，价值 4,637,674 美元。此次交易使其持仓减少了 16.99%。该交易在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，董事 George Poste 于 5 月 7 日星期四出售了 60,000 股公司的股票。该股票以平均价格 45.71 美元出售，总价值为 2,742,600.00 美元。交易完成后，该董事直接持有 118,832 股公司的股票，价值 5,431,810.72 美元。此次交易使其持仓减少了 33.55%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了价值 17,014,813 美元的 382,811 股公司股票。内部人士持有公司 2.60% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>3 Stocks to Buy for a Soft Landing, If There Is One</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只股票值得购买，以应对软着陆，如果真的有的话</li>
</ul>
</div><p>EXEL has been the subject of several recent analyst reports. Royal Bank Of Canada cut their target price on Exelixis from $46.00 to $43.00 and set a &#34;sector perform&#34; rating for the company in a research note on Monday, March 2nd. Truist Financial raised Exelixis to a &#34;strong-buy&#34; rating in a research note on Monday, April 27th. Wells Fargo &amp; Company raised their target price on Exelixis from $35.00 to $40.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Wednesday, May 6th. Stifel Nicolaus raised their target price on Exelixis from $44.00 to $47.00 and gave the stock a &#34;hold&#34; rating in a research note on Wednesday, May 6th. Finally, TD Cowen raised their target price on Exelixis from $51.00 to $55.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus target price of $47.35.</p>
<div class="lb-trans"><p>EXEL 最近成为几份分析师报告的主题。加拿大皇家银行在 3 月 2 日的研究报告中将 Exelixis 的目标价从 46.00 美元下调至 43.00 美元，并对该公司设定了 “行业表现” 评级。Truist Financial 在 4 月 27 日的研究报告中将 Exelixis 的评级提升至 “强力买入”。富国银行在 5 月 6 日的研究报告中将 Exelixis 的目标价从 35.00 美元上调至 40.00 美元，并给予该股票 “等权重” 评级。Stifel Nicolaus 在 5 月 6 日的研究报告中将 Exelixis 的目标价从 44.00 美元上调至 47.00 美元，并给予该股票 “持有” 评级。最后，TD Cowen 在 5 月 6 日的研究报告中将 Exelixis 的目标价从 51.00 美元上调至 55.00 美元，并给予该股票 “买入” 评级。一位研究分析师对该股票给予了 “强力买入” 评级，九位给予了 “买入” 评级，十一位给予了 “持有” 评级，二位对该公司的股票给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价为 47.35 美元。</p>
</div><p><strong>View Our Latest Stock Report on EXEL</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 EXEL 股票报告</strong></p>
</div><h2>Exelixis Trading Down 1.9%</h2>
<div class="lb-trans"><h2>Exelixis 股价下跌 1.9%</h2>
</div><ul>
<li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲的生物技术表现者，值得关注，因为该行业接近突破</li>
</ul>
</div><p>Shares of NASDAQ EXEL opened at $50.13 on Friday. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $51.63. The stock has a fifty day simple moving average of $44.30 and a 200-day simple moving average of $43.48. The stock has a market capitalization of $12.60 billion, a PE ratio of 16.65, a PEG ratio of 1.06 and a beta of 0.38.</p>
<div class="lb-trans"><p>NASDAQ EXEL 的股票在周五开盘时为 50.13 美元。Exelixis, Inc. 的 12 个月低点为 33.76 美元，12 个月高点为 51.63 美元。该股票的 50 日简单移动平均为 44.30 美元，200 日简单移动平均为 43.48 美元。该股票的市值为 126 亿美元，市盈率为 16.65，市盈增长比率为 1.06，贝塔值为 0.38。</p>
</div><p>Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts' consensus estimates of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business had revenue of $610.81 million during the quarter, compared to analysts' expectations of $607.51 million. During the same period in the previous year, the firm posted $0.55 earnings per share. The company's revenue was up 10.0% on a year-over-year basis. On average, equities analysts predict that Exelixis, Inc. will post 3.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近于 5 月 5 日星期二发布了季度收益数据。该生物技术公司报告该季度每股收益为 0.87 美元，超出分析师的共识预期 0.75 美元，超出 0.12 美元。Exelixis 的股本回报率为 39.89%，净利润率为 35.08%。该公司在该季度的收入为 6.1081 亿美元，而分析师的预期为 6.0751 亿美元。在去年同期，该公司每股收益为 0.55 美元。该公司的收入同比增长 10.0%。平均而言，股票分析师预测 Exelixis, Inc. 在当前年度将发布每股收益 3.15 美元。</p>
</div><h2>About Exelixis</h2>
<div class="lb-trans"><h2>关于 Exelixis</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.</p>
<div class="lb-trans"><p>Exelixis, Inc. 是一家生物技术公司，专注于小分子疗法的发现、开发和商业化，主要用于癌症治疗。该公司基于利用模式生物遗传学和高通量筛选的平台，专注于调节肿瘤生长和转移相关的关键信号通路的激酶抑制剂的研究。Exelixis 的转化研究方法旨在将新化合物从早期发现推进到临床开发和监管批准。</p>
</div><p>The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.</p>
<div class="lb-trans"><p>该公司的最知名产品包括 CABOMETYX®（cabozantinib），已获批准用于治疗晚期肾细胞癌和肝细胞癌，以及用于转移性髓样甲状腺癌的 COMETRIQ®（cabozantinib）。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Exelixis</li>
<li>3 Stocks to Own If Gas Prices Keep Rising</li>
<li>3 Crucial Aerospace Component Makers That Analysts Love</li>
<li>Alphabet's Googlebook Brings Gemini AI to PC Hardware</li>
<li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Exelixis</li>
<li>如果油价持续上涨，值得拥有的三只股票</li>
<li>分析师喜爱的三家关键航空航天组件制造商</li>
<li>Alphabet 的 Googlebook 将 Gemini AI 引入 PC 硬件</li>
<li>Peloton 股票在乐观的财报发布后回吐涨幅</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding EXEL?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 EXEL 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EXEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Exelixis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
</div><p>Before you consider Exelixis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Exelixis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Exelixis 并不在名单上。</p>
</div><p>While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Exelixis 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Thrivent Financial for Lutherans Increases Holdings in Exelixis, Inc. $EXEL

Market Beat

美国制药 ETF - iShares

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

加拿大皇家银行

Truist Financial

富国银行

Stifel Financial

Toronto Dominion Bank

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

路德会的 Thrivent Financial 增加了对 Exelixis, Inc. $EXEL 的持股